A New Energy Device for Skin Activation to Acute Wound Using Cold Atmospheric Pressure Plasma: A Randomized Controlled Clinical Trial

Akio Nishijima1-3*, Takahiro Fujimoto2,3, Takamichi Hirata3 and Junko Nishijima2,3

1Department of Plastic and Reconstructive Surgery, Japan
2Clinic F, Japan
3Department of Medical Engineering, Japan

*Corresponding author: Akio Nishijima, Department of plastic and reconstructive surgery, University of Tsukuba, 2-1-1 Amakubo, Tsukuba-shi, Ibaraki, Japan

ABSTRACT

Objectives: The aim of this study was to evaluate Cold Atmospheric Pressure Plasma (CAP) treatment as a novel energy device for skin activation, assisting its anti-inflammatory action and promoting wound healing.

Materials and Methods: This study was a prospective, randomized, open, blinded-endpoint method and controlled trial conducted on the forearms. This study was conducted on 48 regions of 12 healthy volunteer subjects. A fractional CO2 laser was used to irradiate four similarly sized regions on the left forearm. Each region then randomly received one of the following treatments: plasma (radiated with a CAP jet for 60 seconds), betamethasone valerate and gentamicin sulfate, basic fibroblast growth factor, or no treatment. A three-dimensional dermal analysis device was used to measure the a* index (a*I), arithmetical mean roughness (Ra), and average melanin density immediately before and after the laser radiation, and at post-treatment Days 1, 3, 7, 14, and 28.

Results: The day after therapy, a*I of the plasma group was significantly improved compared with the control group (p = 0.03). However, from Day 3, these two groups showed similar tendencies (with no significant differences) in all evaluation items. No complications of pain, infections, or bleeding were observed in any treated regions after laser radiation.

Conclusion: In this study, anti-inflammatory action by the CAP radiation were observed, obtaining a treatment efficacy equivalent to that of conventional therapies. Our findings provide evidence of the effectiveness and safety of CAP and assist the future development of medical plasma therapy.

Introduction

More than a half-century has passed since Maiman’s first success with ruby laser treatment [1-4]. Since then, laser devices have been developed for use in diagnosis and treatment across several fields of medical practice, including those for skin activation. Various energy devices can be used for skin activation, as determined by selective photothermolysis theory. Those currently used with demonstrated clinical efficacy include pulsed lasers 2, fractional lasers 3, radiofrequency devices 4, high-intensity focused ultrasound [5], and selective cryolipolysis [6]. In recent years, plasma treatment to promote skin activation has also been attracting attention, with a rapid increase in interest in medical devices based on Cold Atmospheric Pressure Plasma (CAP). Laroussi first reported the use of atmospheric pressure plasma in 1996 [7]; since then, CAP has been investigated for various biomedical applications using appropriate laboratory testing. Skin activation, such as wound healing, is of particular interest with promising studies demonstrating the benefits of [8].
Our study used Three-Dimensional (3D) dermal analysis equipment in a randomized controlled trial to evaluate the effect of CAP treatment for skin activation during the process of wound healing of acute wounds in humans. We also compared the efficacy of CAP treatment with that of conventional treatments for skin activation.

**Material and Methods**

**Study Design**

This prospective, randomized, open, blinded-endpoint method and controlled trial was conducted from September 2017 to April 2018 (University Hospital Medical Information Network identifier: UMIN000029121) comparing treatments on four similarly sized regions on the left forearms of healthy volunteer subjects. The study protocol was approved by the institutional review board of Tokyo City University (IRB number: 413), and all the subjects provided written informed consent.

**Subjects**

Initially, the study enrolled 15 healthy volunteer subjects (12 women and 3 men) with a mean age of 36.8 ± 12.8 years and Fitzpatrick skin type III or IV, all recruited at the Tokyo City University and Clinic F in metropolitan Tokyo. However, 3 subjects were unable to attend the follow-up appointments regularly, so 12 subjects were included in the analysis. They wore long sleeves to protect their skin from solar radiation. Subjects were excluded if they felt unwilling to be assigned to any of the approaches.

**Creation of Lesions by Randomization**

The 12 subjects each received laser treatment to four areas of the same size (1.5 × 2.0 cm) on the medial side of the left forearm, making a total of 48 treatment regions. Each lesion was created using a fractional CO₂ (FXCO₂) laser therapy device (SmartXide DOT RT®R, DEKA M.E.L.A. srl, Calenzano, Italy) in a single shot at an output power of 10 W, pulse width of 600 μs, dot spacing of 650 μm, and stack 2.

**Intervention**

After FXCO₂ laser therapy, each of the four regions on their arms was subjected to a different treatment: CAP (the CAP group of regions), steroid and antibiotic ointment (ointment group), basic fibroblast growth factor (bFGF group), or no treatment (control group). These interventions were applied only once and were randomly allocated to the regions. The CAP group of regions was subjected to a CAP jet (described below), in accordance with the previously reported laser radiation method for clinical practice [9,10]. The ointment group received a topical application of ointment containing betamethasone valerate and gentamycin sulfate (Rinderon-VG®, Shionogi & Co., Ltd, Tokyo, Japan). The bFGF group received two to three sprays of aerosolized trafermin (genetical recombination) (Fiblast® Spray, Kaken Pharmaceutical Co., Ltd, Tokyo, Japan).

**CAP Treatment**

Plasma was applied to the target region with CAP jets using a kINPen MED® (INP Greifswald/neoplas tools GmbH, Greifswald, Germany) [11]. The device used in this study fulfilled the technical requirements for medical use and consisted of a hand-held unit for the generation of gas discharge under atmospheric pressure conditions and a direct current power supply unit. A high voltage of 2–3 kVpp at a frequency of 1 MHz was periodically applied to the pin electrode (frep = 2.5 kHz, plasma duty cycle = 1:1). The system was operated with argon gas at flow rates between 4 and 6 L/m. Under these working conditions, the plasma jet outside the ceramic capillary was approximately 10 mm long. Plasma treatment for the target area was performed by moving the visible tip of the plasma jet repeatedly over the whole target area for 60 seconds Figure 1.

**Photographic Analysis**

Before and after the treatment, a 3D skin analyzer (ANTERA 3DTM, Miravex Co., Ltd, Ireland) was used to record changes in the irradiated areas and to assess the process of wound healing [12,13].

**Outcome Measurement Methods**

To evaluate the process of wound healing, redness, roughness, and pigmentation on the skin surface were measured. The a* index ($a^*I$) of L*$a^*b$ color space was used to evaluate redness, with higher
values of $a^*$ are indicating more red/violet components and smaller values indicating more blue/green components. The roughness of the skin was evaluated by the Arithmetical Mean Roughness (Ra), presented as the average of the absolute values within the sampling region. Pigmentation was evaluated as the mean melanin concentration, as shown by the ANTERA 3DTM. We established a quantitative evaluation method to assess the rate of change in the treated regions. In general, the condition of a wound is influenced by the patient’s condition and by environmental factors at the time of monitoring the wound. The quantitative evaluation of the skin condition in the present study, therefore, required the treatment regions to be compared with the intact skin near the radiated sites. The mean values of each evaluation measure for each entire treated region before and after the treatment were obtained from the ANTERA 3DTM image data, and the changes were calculated by comparing the data of the laser-radiated regions and the intact skin. The rate of change (%) was calculated by the following equation as shown in Figure 2, where $A$ is the ratio of $a^*$ in the radiated lesion relative to the intact skin before the randomized treatment, and $B$ is that after the randomized treatment:

$$\frac{(B-1)}{(A-1)} \times 100$$

Improvement was defined when a rate of change was less than 100%.

The evaluation items were measured immediately before and after the FXCO$_2$ laser radiation, and at 1, 3, 7, 14, and 28 days after the radiation. The primary outcome was the change in absolute values and the rates of change of $a^*$ and Ra. The secondary outcome was the extent of pigmentation and the safety of the CAP jet treatment at one-month post-treatment. The measurements were made in a blinded manner by a different clinician from the one who performed the treatments.

**Statistical Analysis**

No data from any of the 12 subjects were excluded from any analyses. Categorical data were summarized as the frequency and continuous data as the mean and Standard Deviation (SD). Comparisons between groups were performed using Student’s t-test or one-way analysis of variance for continuous variables. The sample size was defined as $4 \times 4$, based on the Latin square method, because we conducted a randomized study for four regions for each subject. The minimum necessary sample number was determined to be 48 sites in 12 subjects, considering collectible number of data in the institutions. On the basis that some subjects may withdraw during the follow-up period, 15 subjects were initially enrolled in this study. All statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, NC, USA). A p-value < 0.05 was considered statistically significant.

**Results**

**Flow of Subject Inclusion**

The 12 subjects received treatments after randomizing the selection of treatments, and the outcomes were monitored during the follow-up period Figure 3.

---

**Figure 2:** Definition Of rate of change in this study.

Normal intact skin (a and b) and regions received treatment (c and d) are plotted.

$$A = \frac{c}{a}$$

$$B = \frac{b}{d}$$

Rate of change (%) = \( \frac{(B-1)}{(A-1)} \times 100 \)
**Primary Outcomes**

**CAP group vs. Control Group:** Figure 4 shows the time course of a*I for the CAP and control groups of treated regions. On the first day following treatment (Day 1), there was a deterioration in a*I in the control group, but an improvement in the CAP group. Figure 5 shows the time course of Ra for the CAP and control groups. (Table 1) presents the absolute values and rates of change of a*I and Ra in the CAP and control groups on Day 1. The results for a*I showed a significant improvement in the CAP group (p = 0.03). Figure 6A shows representative findings on the medial surface of the left forearm immediately after FXCO₂ laser radiation, Figure 6B shows the time courses of a*I, Ra, and melanin concentration of the CAP and control groups by visualization using ANTERA 3DTM.

![Image of CONSORT flow chart](image-url)

**Figure 3:** CONSORT flow chart of subject inclusion in our study.

![Image of CONSORT flow chart](image-url)

**Figure 4:** Transition of a*Index in the CPA group and control group.

Note: At 1st post-treatment day, a*I of the control group worsened, but that of CAP group improved. (CAP = Cold Atmospheric Pressure Plasma)

<table>
<thead>
<tr>
<th>Table 1: Absolute values and rate of change of a*I and Ra in the control group and the CAP group on 1st post-treatment day.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Control group</strong> (n = 12)</td>
</tr>
<tr>
<td>Mean a*I ± SD</td>
</tr>
<tr>
<td>Change rate of a*I ±SD (%)</td>
</tr>
<tr>
<td>Mean Ra ± SD</td>
</tr>
<tr>
<td>Change rate of Ra ± SD (%)</td>
</tr>
</tbody>
</table>

Note: a*I showed significant improvement in the CAP group.

Abbreviations: a*I, a* index of of L*a*b color space; Ra, arithmetical mean roughness; CAP, Cold Atmospheric Pressure Plasma, SD, standard deviation;
Figure 5: Transition of Ra in the CPA group and control group.
Note: At 1st post-treatment day, Arithmetical Mean Roughness (Ra) of both groups reduced, then increased till 7th post-treatment day. At 28th post-treatment day, both groups showed almost equivalent Ra compared with that before treatment. (CAP = cold atmospheric pressure plasma)

Figure 6: Evaluation of wound healing:
(A) Findings immediately after FXCO2 laser radiation to the medial surface of the left lower forearm and a randomized example of four-type treatments.
(B) Transitions of a*I, Ra, and melanin concentration of the CAP group and control group, which were visualized by a 3D skin analyzer (ANTERA 3DTM).

CAP, Ointment, and bFGF Groups: Table 2 shows a*I and Ra for the three treatment groups. No significant differences were observed between the CAP, ointment, and bFGF groups at any time point. Also, there were no significant differences in the rates of change.
**Table 2**: a* I and Ra in 3 treatment groups (CAP, ointment, and bFGF).

<table>
<thead>
<tr>
<th>Time</th>
<th>n</th>
<th>CAP (Mean ± SD)</th>
<th>Ointment (Mean ± SD)</th>
<th>bFGF (Mean ± SD)</th>
<th>p-value</th>
<th>CAP (Mean ± SD)</th>
<th>Ointment (Mean ± SD)</th>
<th>bFGF (Mean ± SD)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediately after treatment</td>
<td>20</td>
<td>16.5±1.9</td>
<td>17.0±1.6</td>
<td>16.5±2.3</td>
<td>0.78</td>
<td>3.9±0.8</td>
<td>3.8±0.8</td>
<td>4.1±0.7</td>
<td>0.58</td>
</tr>
<tr>
<td>1st day</td>
<td>20</td>
<td>15.2±2.3</td>
<td>14.8±2.1</td>
<td>16.5±3.5</td>
<td>0.3</td>
<td>3.0±0.8</td>
<td>2.9±0.6</td>
<td>3.1±0.6</td>
<td>0.81</td>
</tr>
<tr>
<td>3rd day</td>
<td>20</td>
<td>14.3±1.9</td>
<td>13.7±1.6</td>
<td>14.0±3.2</td>
<td>0.82</td>
<td>3.8±1.0</td>
<td>3.5±0.8</td>
<td>3.9±1.1</td>
<td>0.78</td>
</tr>
<tr>
<td>7th day</td>
<td>20</td>
<td>13.2±1.9</td>
<td>12.5±1.2</td>
<td>12.8±2.2</td>
<td>0.69</td>
<td>3.0±0.9</td>
<td>3.7±0.6</td>
<td>4.0±0.8</td>
<td>0.6</td>
</tr>
<tr>
<td>14th day</td>
<td>20</td>
<td>12.5±1.6</td>
<td>12.4±0.9</td>
<td>12.3±1.6</td>
<td>0.93</td>
<td>3.0±0.9</td>
<td>2.8±0.7</td>
<td>3.0±0.7</td>
<td>0.71</td>
</tr>
<tr>
<td>28th day</td>
<td>20</td>
<td>11.8±1.7</td>
<td>11.5±0.9</td>
<td>11.5±2.2</td>
<td>0.90</td>
<td>2.4±0.4</td>
<td>2.4±0.4</td>
<td>2.4±0.4</td>
<td>0.95</td>
</tr>
</tbody>
</table>

Secondary Outcomes

The mean melanin concentrations at Day 28 in the control, CAP, ointment, and bFGF groups were 0.52 ± 0.06, 0.52 ± 0.07, 0.50 ± 0.04, and 0.53 ± 0.06, respectively, with no significant differences between the groups (p = 0.81). No complications, including pain, infection, or bleeding, were observed in any treated region.

Discussion

Overview of Plasma Devices for Skin Activation

In 1928, plasma was defined by Irving Langmuir as a state in which there is electrolytic dissociation of the molecules that comprise a gas, where the cations of the molecules and electrons are moving. Arsonvalization was one of the most convenient of the popular electromedical treatments, classified as high-frequency therapy; it had much in common with modern CAP treatment, at least regarding its bioactive properties [14,15]. Jacques-Arne d’Arsonval discovered the possibility of influencing the human body with high frequencies delivered by his apparatus with the help of extremely high transformation of electric tension [16]. The device was further developed in Germany for a caloric treatment of patients called diathermy, and Rumpf et al. developed a device that differed from the French ones by implementing a capacitively coupled electrode consisting of a Leydener bottle, which was directly applied to the patient’s skin [16]. This device can be considered the first plasma source in medicine to use a dielectric electrode.

These days, continuous radiation to the skin is technically possible by using CAP. At a reduced cost and without the need for vacuum equipment, CAP allows the target object to be directly processed with plasma. The kINPen MED device used in this study was the first CAP jet apparatus to receive accreditation worldwide as a medical device (class IIa). Its reusable argon plasma jet can generate a constant, non-thermal (room temperature) plasma at atmospheric pressure [15].

Effect of CAP as a Novel Energy Device for Skin Activation

**Medical Plasma has Two major Effects**: Antibacterial action and tissue activation. In clinical practice, the antibacterial action of medical plasma has been attracting attention, especially for the treatment of chronic ulcers such as venous stasis skin ulcers or diabetic foot gangrene [8]. Many types of bacteria and fungi that are categorized as physiological or pathological skin flora are highly susceptible to plasma treatment [17].

In this study, we focused on medical plasma’s biological tissue activation effects in acute phase wounds. The significant improvement in redness (a* I) in the regions treated with CAP compared with the control regions demonstrated the anti-inflammatory effect of plasma. The process of wound healing is characterized by four continuous, overlapping, and precisely programmed phases:

1) Hemostasis,
2) Inflammation,
3) Proliferation, and
4) Remodeling [18,19].

During all these phases, plasma-derived activation species activate growth factors. Plasma contains many neutral molecules, ion species, and radical species. Nitric oxides are generated when the atmosphere is used as a source for plasma. In 1987, NO was found to play a major part in endothelium-derived relaxing factor, which controls blood flow; blood flow improves after plasma radiation [20]. Hirata et al. reported increased neovascularity with plasma radiation and concluded that the surface reaction of tissue to an electrochemical stimulus activated growth factors and accelerated healing in a gas phase because of the generation of active oxygen, such as Ozone (O$_3$) and Hydroxyl radical (OH$_-$) and active nitrogen, such as NO and nitrogen dioxide (NO$_2$) [21]. Immediately after the FXCO$_2$ laser treatment, the Ra of the irradiated skin increased because of swelling. Although no significant differences of Ra were noted between the CAP group and control group, the rate of Ra reduction was greater in the CAP group the day after radiation, indicating a faster reduction in swelling. So, if the wound is more severe than this case, the effects of CAP would be expected to be greater.

The excessive generation of NO carries a risk of inducing abnormality in tissues. We, therefore, evaluated whether activating species caused pigmentation in the skin by measuring CAP-induced melanin concentrations in the irradiated sites. By Day 28, the subjects’ skin color had returned to that before laser radiation,
indicating that the radiation parameters in our study were not a problem. Metelmann et al. monitored radiated lesions for 12 months and reported no delayed side effects, such as carcinogenesis or hypertrophic cicatrization. Figure 7 shows the relationship between the activating species generated after plasma radiation and skin activation, based on our study findings.

Figure 7: Potential therapies of Cold Atmospheric Pressure Plasma (CAP) promoting wound healing and reducing scar formation during wound repair. (ROS, reactive oxygen species; RNS, reactive nitrogen species).

Roles and Future Prospect of Cap in Medical Practice

There were no significant differences in any of the evaluated items between the groups treated with CAP, ointment, and bFGF. Steroids are often used as an anti-inflammatory drug for wounds without infection, including skin troubles after FXCO₂ laser treatment. We observed an improvement in redness, compared with the control group, in the group of irradiated regions treated with ointment containing steroids, confirming its anti-inflammatory action. However, although the incidence is low, steroidal drug use carries a risk of developing adverse reactions, including steroid acne, steroid rosacea, peristome dermatitis, excessive hair growth, steroid peliosis, skin atrophy, infection disease, contact dermatitis, and pigmentation. Caution is therefore needed to avoid severe burning or skin injury to the face. In Japan, the use of bFGF is covered by national health insurance for the treatment of compression gangrene or skin ulcers, so it is often applied in clinical practice. However, issues with bFGF include its high cost (about US$83.60 for a 5 mL bottle), the need for cold storage, the short effective time for consumption (within 2 weeks), and its lack of antibacterial effects. Steroids and bFGF preparation cannot be shared with other patients after opening their containers, which means that waste of medical resources often becomes an issue. This meant more objective evaluations, including cellular and molecular evaluations, were not available. To confirm our conclusions, a multi-institutional large-scale randomized controlled trial, including molecular analysis, is necessary.

Conclusion

Our randomized controlled trial showed the clinical efficacy of CAP as a new energy device for skin activation. The CAP treatment equivalent to that of steroid ointment, the capability for continuous radiation for each patient, and no side effects. Plasma treatment is therefore considered to be effective for post-fractional laser treatment, not just for general injuries. Since medical plasma for skin treatment is simple and safe, and there is abundant evidence of its efficacy, it is considered a promising treatment, with further development expected in the future.
by applying plasma jet resulted in anti-inflammatory action, with efficacy equivalent to that of conventional therapies. Our findings provide confirmatory evidence of the effectiveness and safety of CAP and may assist the future development of medical plasma therapy.

References

ISSN: 2574-1241
DOI: 10.26717/BJSTR.2019.21.003532
Akio Nishijima, Biomed J Sci & Tech Res

This work is licensed under Creative Commons Attribution 4.0 License
Submission Link: https://biomedres.us/submit-manuscript.php

Assets of Publishing with us
• Global archiving of articles
• Immediate, unrestricted online access
• Rigorous Peer Review Process
• Authors Retain Copyrights
• Unique DOI for all articles

https://biomedres.us/